Valerian: Valeriana officinalis

American Journal of Health-System Pharmacy

Volumn 57, Issue 4, 2000, Pages

  Plushner, Susyn L ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT; HOVA; HYPNOTIC SEDATIVE AGENT; KALMS; NEURELAX; SESQUITERPENE; UNCLASSIFIED DRUG; VALEPOTRIATE; VALERIAN;

ANXIETY NEUROSIS; DOSE RESPONSE; DRUG MECHANISM; HUMAN; LIVER TOXICITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; SEDATION; SHORT SURVEY; SLEEP DISORDER; TRADITIONAL MEDICINE; TRANQUILIZING ACTIVITY; TREATMENT INDICATION;

EID: 0343851571     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/57.4.328     Document Type: Short Survey

References (21)

1. Bisset NG. Herbal drugs and phytopharmaceuticals. Stuttgart, Germany: Medpharm GmbH Scientific; 1994.
2. Hobbs C. Valerian. Herbalgram. 1989; 21:19-34.
3. Leathwood PD, Chauffard F. Aqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in man. Pharmacol Biochem Behav. 1982; 17:65-71.
4. Houghton PJ. The scientific basis for the reputed activity of valerian. J Pharm Pharmacol. 1999; 51:505-12.
5. Lindahl O, Lindwall L. Double blind study of a valerian preparation. Pharmacol Biochem Behav. 1989; 32:1065-6.
6. Schulz H, Stolz C, Muller J. The effect of valerian extract on sleep polygraphy in poor sleepers: a pilot study. Pharmacopsychiatry. 1994; 27:147-51.
7. Mennini T, Bernasconi P, Bombardelli E et al. In vitro study on the interaction of extracts and pure compounds from Valeriana officinalis roots with GABA, benzodiazepine and barbituate receptors in rat brain. Filoterapia. 1993; 64:291-300.
8. Santos MS, Ferreira F, Cunha AP et al. An aqueous extract of valerian influences the transport of GABA in synaptosomes. Planta Med. 1994; 60:278-9.
9. 3H] GABA release in synaptosomes. Planta Med. 1994; 60:475-6.
10. Hendriks H, Bos R, Woerdenbag HJ et al. Central nervous depressant activity of valerenic acid in the mouse. Planta Med. 1985; Feb: 28-31.
11. Hiller KO, Zetler G. Neurophamacological studies on ethanol extracts of Valeriana officinalis L.: behavioural and anticonvulsant properties. Phytother Res. 1996; 10:145-51.
12. Leuschner J, Muller J, Rudmann M. Characterisation of the central nervous depressant activity of a commercially available valerian root extract. Arzneimittelforschung. 1993; 43:638-41.
13. Andreatini R, Leite JR. Effect of valepotriates on the behavior of rats in the elevated plusmaze during diazepam withdrawal. Eur J Pharmacol. 1994; 260:23-5.
14. Leathwood PD, Chauffard F. Aqueous extract of valerian reduces latency to fall asleep in man. Planta Med. 1985; Apr: 144-8.
15. Leathwood PD, Chauffard F. Quantifying the effects of mild sedatives. J Psychiatr Res. 1982/83; 17:115-22.
16. Balderer G, Borbely A. Effect of valerian on human sleep. Psychopharmacology. 1985; 87:406-9.
17. Kohnen R, Oswald W-D. The effects of valerian, propranolol, and their combination on activation, performance, and mood of healthy volunteers under social stress conditions. Pharmacopsychiatry. 1988; 21:447-8.
18. Garges HP, Varia I, Doraiswamy PM. Cardiac complications and delirium associated with valerian root withdrawal. JAMA. 1998; 280:1566-7.
19. MacGregor FB, Abernethy VE, Dahabra S et al. Hepatotoxicity of herbal remedies. Br Med J. 1989; 299:156-7.
20. Tufik S, Fujita K, de Lourdes M et al. Effects of a prolonged administration of valepotriates in rats on the mothers and their offspring. J Ethnopharmacol. 1994; 41:39-44.
21. Bounthanh C, Bergmann C, Beck JP et al. Valepotriates, a new class of cytotoxic and antitumor agents. Planta Med. 1981; 41:21-8.